4) Immune-related Adverse Event and Its Management
نویسندگان
چکیده
منابع مشابه
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
Immunotherapy is one of the most recent systemic treatments to emerge for use in oncology, and is based on the blocking of inhibitory immune checkpoints to potentiate the immune response to cancer. The anti-cytotoxic T lymphocyte-associated antigen-4 antibody ipilimumab and anti-programmed cell death protein 1 antibodies, including nivolumab and pembrolizumab, are currently available and widely...
متن کاملAdverse Event Management
The Brazilian Journal of Infectious Diseases 2007;11 (5) Suppl. 1:66-70. © 2007 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved. The treatment of hepatitis C involves combining conventional interferon (IFN) or pegylated IFN (PEG-IFN) with ribavirin (RBV). These therapeutic regimens are associated with numerous adverse events, among which constitution...
متن کاملA systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.
BACKGROUND There are limited data about the quality of immune-related adverse event (irAE) reporting in immune checkpoint inhibitor (ICI) clinical trial publications. METHODS A systematic search of citations from Medline, EMBASE and Cochrane databases identified prospective clinical trials involving ICIs in advanced solid tumors from 2003 to 2013. A 21-point quality score (QS) was adapted fro...
متن کاملExperience with sorafenib and adverse event management.
Sorafenib was the first multikinase inhibitor to be approved for use in renal cell cancer (RCC) in the US (2005) and in Europe (2006). In the Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET), sorafenib showed a significant progression-free survival advantage over placebo in patients with advanced RCC. Incidence rates of adverse events were significantly higher with sor...
متن کاملClinical assessment of immune-related adverse events
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across div...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2020
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.109.118a